NCT04825561已完成3 期
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AD-208 in Male Patients With Androgenetic Alopecia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 139
- 试验地点
- 1
- 主要终点
- The amount of Change in the total number of hairs
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of AD-208.
详细描述
The purpose of this study is to evaluate the efficacy and safety of AD-208 in male patients with androgenetic alopecia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male patients aged 18-50 years, inclusive
- •Patients who meet the appropriate criteria according to the classification of hair loss
- •Signed informed consent
排除标准
- •Patients with hair loss disorders other than androgenetic alopecia
- •Other exclusions applied
研究组 & 干预措施
Active Comparator
Active Comparator
AD-208 and Placebo of AD-2081
干预措施: AD-208 (Drug)
Active Comparator
Active Comparator
AD-208 and Placebo of AD-2081
干预措施: placebo of AD-2081 (Drug)
Placebo Comparator
Placebo Comparator
Placebo of AD-208 and Placebo of AD-2081
干预措施: placebo of AD-208 (Drug)
Placebo Comparator
Placebo Comparator
Placebo of AD-208 and Placebo of AD-2081
干预措施: placebo of AD-2081 (Drug)
Experimental Comparator
Experimental
Placebo of AD-208 and AD-2081
干预措施: AD-2081 (Drug)
Experimental Comparator
Experimental
Placebo of AD-208 and AD-2081
干预措施: placebo of AD-208 (Drug)
结局指标
主要结局
The amount of Change in the total number of hairs
时间窗: Baseline, Week 24
The amount of change in the total number of hairs in the unit area
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
A Study to Evaluate the Efficacy and Safety of AD-218Mixed DyslipidemiaNCT05400317Addpharma Inc.520
已完成
3 期
A Study to Evaluate the Efficacy and Safety of AD-224Hypertension,EssentialNCT06291207Addpharma Inc.254
已完成
3 期
A Study to Evaluate the Efficacy and Safety of AD-223Hypertension,EssentialNCT06052748Addpharma Inc.502
已完成
1 期
A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.AsthmaNCT01928368Amgen70
已完成
3 期
A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221APrimary HypercholesterolemiaNCT05131997Addpharma Inc.290